Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Eli Lilly received FDA approval last July for Kisunla (generic name donanemab), a treatment that removes amyloid plaque accumulation in the brain. Domestic researchers have developed a new system ...
Verywell Health on MSN5d
What's New in Alzheimer's Treatment?We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...
Alzheimer's disease Therapeutics Market. LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- DelveInsight's“Acute Respiratory Distress Synd ...
Verywell Health on MSN8d
Injectable Alzheimer's Drugs Could Save Patients Trips to the HospitalEisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...
Bloomberg on MSN8d
Alzheimer’s drugs eyed as next big obesity-like opportunityInvestors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback